Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab combined with chemotherapy as first-line treatment for MSI-H/dMMR advanced gastric cancer
ChiCTR2100054181Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Dec 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, oxaliplatin, fluorouracil, capecitabine and tegafur in gastric cancer (GC), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: 12-month progression-free survival rate. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
camrelizumaboxaliplatinfluorouracilcapecitabinetegafur
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR2100054181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054181.